These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31990987)

  • 1. Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Gugliotta G; Castagnetti F; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    Hematol Oncol; 2020 Apr; 38(2):201-203. PubMed ID: 31990987
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
    Neelakantan P; Marin D; Laffan M; Goldman J; Apperley J; Milojkovic D
    Haematologica; 2012 Sep; 97(9):1444. PubMed ID: 22532521
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
    Nazha A; Romo CG; Kantarjian H; Cortes J
    Haematologica; 2013 Oct; 98(10):e131. PubMed ID: 24091930
    [No Abstract]   [Full Text] [Related]  

  • 7. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.
    Mancini M; Castagnetti F; Soverini S; Leo E; De Benedittis C; Gugliotta G; Rosti G; Bavaro L; De Santis S; Monaldi C; Martelli M; Santucci MA; Cavo M; Martinelli G
    J Cell Biochem; 2017 Nov; 118(11):3968-3975. PubMed ID: 28401599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1.
    Hassanzadeh A; Hosseinzadeh E; Rezapour S; Vahedi G; Haghnavaz N; Marofi F
    Anticancer Agents Med Chem; 2019; 19(12):1523-1534. PubMed ID: 31362681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B; Wang C; Li J; Du X; Ding K; Pan J
    Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
    Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
    Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.
    Kayabasi C; Caner A; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Asik A; Mutlu Z; Caliskan Kurt C; Goker Bagca B; Biray Avci C; Sahin F; Saydam G; Gunduz C
    Med Oncol; 2022 Jan; 39(3):29. PubMed ID: 35059859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.
    Yang N; Wang C; Wang Z; Zona S; Lin SX; Wang X; Yan M; Zheng FM; Li SS; Xu B; Bella L; Yong JS; Lam EW; Liu Q
    Oncogene; 2017 Jun; 36(24):3428-3440. PubMed ID: 28114286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib (Iclusig) for CML and Ph+ ALL.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
    Okabe S; Tanaka Y; Moriyama M; Gotoh A
    Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
    [No Abstract]   [Full Text] [Related]  

  • 19. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
    Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.